Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
NICE guidance (TA875, 2023) recommends that Wegovy is used as an adjunct to a reduced-calorie diet and increased physical activity, and that it is prescribed within specialist weight management services
The safety data available derive from Phase 2 clinical trials (Jastreboff et al., NEJM, 2023), which, whilst informative, represent a relatively limited population and duration of follow-up compared to post-marketing surveillance
The published surveillance data has not identified an increased melanoma rate in the small EPP-treated population
Online visit
However, the higher dose was associated with increased rates of dysesthesia and related sensory effects, reported in 22% of patients compared with 6% for the 2.4 mg dose
